Which products are genuinely better made in microgravity, what does it cost to make and return them, and is the demand large enough to support capsules and commercial stations?
The short answer. fewer than the industry's marketing suggests, and the best-proven one is not a product at all. After more than 1,000 sponsored payloads on the International Space Station, the clearest commercial outcomes are research insights that companies then reproduce on Earth: Merck's space-grown pembrolizumab crystals informed a subcutaneous formulation the FDA approved in September 2025, but the medicine is made on the ground. The first company to fly and return capsules routinely, Varda Space Industries, has landed several since 2024 and raised about $598 million, yet much of its flown work so far has been hypersonic re-entry testing for the US military. On Setcoin's arithmetic a free-flying capsule mission costs about $8 million and returns a few kilograms of product, or roughly $1.6–2.7 million per kilogram. That clears the bar only for products worth millions of dollars per kilogram and hard to copy on Earth: biologic drug crystals, implant films such as artificial retinas and exotic optical fibre. Setcoin's readiness scorecard ranks re-entry test flights first (94 of 100), then artificial retina films, organoid disease models and ZBLAN fibre; making biologic drug substance in orbit ranks last.
Ten findings
| # | Finding | Chapter |
|---|---|---|
| 1 | Microgravity removes convection and sedimentation; the advantage is real for crystals, some tissues and some glasses | Chapter 4 |
| 2 | Most commercial value so far is research insight that is then replicated on Earth | Chapter 14 |
| 3 | Free-flying capsules now fly and return regularly; only Varda has done it repeatedly | Chapter 40 |
| 4 | A capsule mission costs about $8 million and returns a few kilograms (Setcoin estimate) | Chapter 51 |
| 5 | Only products worth millions of dollars per kilogram can bear that cost | Chapter 51, Chapter 57 |
| 6 | A blockbuster biologic needs hundreds of kilograms of drug a year; a space step must be a small, high-value part of the process | Chapter 53 |
| 7 | Defence re-entry testing is the sector's most dependable buyer today | Chapter 62 |
| 8 | No regulator has approved a medicine made in orbit; the UK set out a pathway in March 2026 | Chapter 66, Chapter 68 |
| 9 | The ISS retires at the end of 2030; commercial stations are late, so capsules matter more | Chapter 37 |
| 10 | Published market sizes for 2026 range from $1.4 billion to $7.6 billion because definitions differ | Chapter 64 |
Key numbers
| Measure | Value | Source |
|---|---|---|
| ISS National Lab payloads since 2011 | More than 1,000 | ISS National Lab, Sept 2026 |
| Payloads delivered in FY2025 | 115, about 80% commercial | ISS National Lab FY25 report |
| NASA price to return 1 kg from the ISS | $40,000 | NASA commercial price list (2021) |
| NASA price for one hour of crew time | $130,000 | NASA commercial price list (2021) |
| Varda capital raised | About $598 million, incl. $251M Series D (Sept 2026) | Company |
| ZBLAN fibre drawn on the ISS in one month | 11.9 km | Flawless Photonics, 2024 |
| Setcoin capsule mission cost (reference) | ~$8.1 million | Chapter 51 |
| Cost per usable kilogram returned (reference) | ~$2.7 million | Chapter 51 |
The readiness scorecard in one table
Exhibit 1.2
Re-entry testing leads; artificial retina films are the top product
Score (0–100) · The readiness scorecard in one table
View the data table (13 rows)
| Rank | Product or service | Score (0–100) | Tier |
|---|---|---|---|
| 1 | Hypersonic re-entry test flights (service) | 94 | Proven demand |
| 2 | Artificial retina films | 72 | Near-term |
| 3 | Organoids and disease models (R&D) | 70 | Near-term |
| 4 | ZBLAN optical fibre | 69 | Near-term |
| 5 | Parts printed for use in space | 67 | Near-term |
| 6 | Formulation insight for biologics (R&D) | 64 | Near-term |
| 7 | Protein crystals for structure (R&D) | 63 | Near-term |
| 8 | Small-molecule polymorphs made in orbit | 61 | Near-term |
| 9 | Semiconductor substrate crystals | 58 | Long-dated |
| 10 | Alloys and metallic glasses | 56 | Long-dated |
| 11 | Stem-cell expansion | 53 | Long-dated |
| 12 | Bioprinted tissue and organs | 47 | Long-dated |
| 13 | Biologic drug substance made in orbit | 42 | Long-dated |
Setcoin scorecard. evidence of microgravity advantage, value per kilogram, difficulty of replicating on Earth, clarity of the regulatory path and demand that could fill flights, each scored 1–5 and weighted 25/20/25/15/15. Method in Chapter 10; full ranking in Chapter 33.
The five interactive models
| Model | Question it answers |
|---|---|
| Readiness score | Which products rank highest when you weight the evidence your way? (Chapter 33) |
| Cost per kg returned | What does a capsule mission cost per kilogram of usable product? (Chapter 51) |
| Dose arithmetic | How many capsules would a medicine need, and what would they add to each dose? (Chapter 53) |
| Platform choice | Is a station or a free-flying capsule cheaper for a given experiment? (Chapter 55) |
| Materials break-even | What price must fibre, wafers or films fetch to cover a mission? (Chapter 57) |
Each model can be downloaded as a spreadsheet with live formulas.
How the study is organised
| Part | Chapters | Content |
|---|---|---|
| I. Foundations | Chapter 2 to Chapter 10 | Definitions, physics, history, the ISS evidence base, method |
| II. Products | Chapter 12 to Chapter 33 | Proteins, formulations, polymorphs, biologics, organoids, stem cells, bioprinting, retinas, semiconductors, fibre, alloys, parts for space use, the scorecard |
| III. Platforms | Chapter 35 to Chapter 50 | ISS, commercial stations, capsules, Varda, other capsules, China, recovery, licensing, launch, automation |
| IV. Economics | Chapter 51 to Chapter 64 | Cost per kg, dose arithmetic, platform choice, materials break-even, customer economics, capital, defence demand, market size |
| V. Regulation and regions | Chapter 66 to Chapter 74 | FDA, UK, EU, Europe, Asia, US policy |
| VI. Outlook and tools | Chapter 76 to Chapter 89 | Scenarios, capsule demand, gates, the case for and against, lessons, checklist, implications, risks, signals, questions, method |
Appendices. A, product reference table; B, glossary; C, Setcoin's capsule and platform dataset.
Reading paths
| Reader | Suggested path |
|---|---|
| Pharmaceutical or biotech executive | Chapters 14, 18, 53, 59, 66, 68, 84 |
| Space company | Chapters 33, 39, 40, 51, 62, 77, 86 |
| Government and regulator | Chapters 35, 37, 47, 66, 68, 74 |
| Capital provider | Chapters 1, 33, 51, 61, 64, 80, 87 |
| Newcomer | Chapters 2, 4, 6, 9, 91 |
How this study relates to the series
This is the tenth study in Setcoin's space research programme and the companion to Study S2 (Commercial Space Stations), which analyses the stations that would host much of this work after 2030. Study S5 (launch economics) supplies the launch prices used here; Study S7 (supply chain) covers the capsule and heat-shield parts. Facts are as of October 2026; Setcoin calculations and illustrations are labelled. The study uses public information only.